Antisense compositions and methods of making and using same
The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.
1. An oral dosage form comprising an amount of anti-SMAD7 antisense oligonucleotide comprising the nucleotide sequence of SEQ ID NO:1, wherein all internucleoside linkages in the anti-SMAD7 antisense oligonucleotide are O,O-linked phosphorothioates, or a pharmaceutically acceptable salt thereof, wherein about 10% to about 30% of the amount of the anti-SMAD7 antisense oligonucleotide is released in an environment of pH of 6.6 from the oral dosage form over a period of 30 minutes in an HPLC dissolution method and substantially none of the amount of anti-SMAD7 antisense oligonucleotide is released from the oral dosage form in an environment of pH of 1.0 over a period of 120 minutes in an HPLC dissolution method.
2. An oral dosage form comprising an amount of anti-SMAD7 antisense oligonucleotide comprising the nucleotide sequence of SEQ ID NO:1, wherein all internucleoside linkages in the anti-SMAD7 antisense oligonucleotide are O,O-linked phosphorothioates, or a pharmaceutically acceptable salt thereof, wherein not more than about 50% of the amount of the anti-SMAD7 antisense oligonucleotide is released in an environment of pH of 6.6 from the oral dosage form over a period of 30 minutes in an HPLC dissolution method and substantially none of the amount of anti-SMAD7 antisense oligonucleotide is released from the oral dosage form in an environment of pH of 1.0 over a period of 120 minutes in an HPLC dissolution method.
3. An oral dosage form comprising an amount of anti-SMAD7 antisense oligonucleotide comprising the nucleotide sequence of SEQ ID NO:1, wherein all internucleoside linkages in the anti-SMAD7 antisense oligonucleotide are O,O-linked phosphorothioates, or a pharmaceutically acceptable salt thereof, wherein substantially none of the amount of the anti-SMAD7 antisense oligonucleotide is released in an environment of pH of 1.0 from the oral dosage form over a period of 120 minutes in an HPLC dissolution method.
4. The oral dosage form of any one of claims 1 - 3 , wherein the HPLC dissolution method is performed at 37° C. in a USP/EP Type 2 apparatus having a paddle rotating at 100 rpm.
5. The oral dosage form of claim 4 , wherein the environment of pH 6.6 comprises a phosphate buffer and the environment of pH of 1.0 comprises hydrochloric acid.
6. The oral dosage form of any one of claims 1 - 3 , wherein the oral dosage form comprises an enteric coating.
7. The oral dosage form of claim 6 , wherein the enteric coating comprises cellulose acetate phthalate, methyl acrylate-methacrylic acid copolymer, cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, methyl methacrylate-methacrylic acid copolymer, ethylacrylate-methacrylic acid copolymer, methacrylic acid copolymer type C, polyvinyl acetate phthalate or cellulose acetate phthalate.
8. The oral dosage form of claim 6 , wherein the enteric coating comprises ethylacrylate-methacrylic acid copolymer.
9. The oral dosage form of any one of claims 1 - 3 , wherein the oral dosage form is a tablet.